| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -0.6 | -1.5 |
| Net income | -0.6 | -1.5 |
| EPS (diluted, $ a share) | $-0.08 | $-1.52 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +16.7% |
|---|
10-Q filed with the SEC, NYSE: IBO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Impact Biomedical Inc.: key numbers
- Share price
- $4.91Close, Nov 16
- Market cap
- $42.4M
- Shares outstanding
- 8.64MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Impact Biomedical Inc.
All →Impact Biomedical M&A Deal with Zoar Limited
Impact Biomedical Inc. announced that the SEC has declared effective the Form F-4 registration statement for its proposed merger with Zoar Limited. A special meeting of stockholders to approve the business combination is scheduled for November 13, 2026, with the combined company expected to trade under the ticker symbol 'ZOAR'.
- Counterparty
- Zoar Limited
Impact Biomedical Reverse Stock Split
Impact BioMedical Inc. implemented a 1-for-12.62 reverse stock split of its common stock effective September 23, 2026. The split reduced the number of outstanding shares from approximately 107.8 million to 8.6 million to adjust the company's capital structure. The stock began trading on a split-adjusted basis on the NYSE American under the existing ticker symbol 'IBO'.
Impact Biomedical M&A Deal with Zoar Limited
Impact Biomedical Inc. announced the filing of a Form F-4 registration statement by Zoar Limited in connection with their previously announced business combination. The filing represents a major milestone toward closing the merger, which will result in a combined pharmaceutical company focused on active pharmaceutical ingredients and special therapeutic treatments. The transaction remains subject to SEC effectiveness, stockholder approval, and NYSE American listing approval.
- Counterparty
- Zoar Limited
Impact Biomedical Reverse Stock Split
Impact Biomedical Inc. announced a 1-for-12.62 reverse stock split effective September 23, 2026, reducing outstanding shares from approximately 107.8 million to 8.5 million. The split is intended to regain compliance with NYSE American listing requirements and facilitate its proposed merger with Zoar Limited. Following the split and merger closing, Impact stockholders are expected to receive one share of Zoar Limited for every one share of Impact common stock held.
- Counterparty
- Zoar Limited